New NICE Heart Failure Guidelines What do they mean for primary and secondary care, and patients?

Similar documents
Diagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham

Heart Failure Acute and Chronic

NICE Chronic Heart Failure Guidelines in Adults 2018

Enhancing the Quality of Heart Failure Care

The ACC Heart Failure Guidelines

Enhancing the Quality of Heart Failure Care

Heart Failure (HF) - Primary Care Flow Charts. Pre diagnosis Symptoms or signs suggestive of HF

Heart Failure (HF) - Primary Care Flow Charts. Symptoms or signs suggestive of HF. Pre diagnosis. Refer to the Heart Failure Clinic at VHK for

8:30-10:30 WS #4: Cardiology :00-13:00 WS #11: Cardiology 101 (Repeated)

NT-proBNP: Evidence-based application in primary care

NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT

TEACH & TREAT Post-Myocardial Infarction Left Ventricular Systolic Dysfunction

Heart Failure from a GP perspective

PRESS RELEASE. New NICE guidance will improve diagnosis and treatment of chronic heart failure

Heart Failure. Optimising treatment and balancing co-morbidity in the community. Andrew Ludman Cardiologist

Congestive Heart Failure: Outpatient Management

The CCS Heart Failure Companion: Bridging Guidelines to your Practice

What s new in Heart Failure care?

New in Heart Failure SGK autumn session 2012

Management of chronic heart failure: pharmacology. Giuseppe M.C. Rosano, MD, PhD, FHFA

Heart Failure 101 The Basic Principles of Diagnosis & Management

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

UPDATES IN MANAGEMENT OF HF

Disclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017

From PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group

SGK 2016 Session: Postgraduate Course in Heart Failure Lausanne, 15. June 2016 Heart Failure Guidelines 2016

Summary/Key Points Introduction

21/06/2018. MEASURING PERFORMANCE (AUDIT AND QUALITY IMPROVEMENT) Towards Reducing Inequity. What should we be measuring?

1000 Lives Key Components of Reliable, Evidence-Based Chronic Heart Failure Care how do we compare?

Disclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17

Heart Failure. A Marvellous Story with More to Come. Prof Ken McDonald National Clinical Lead for Heart Failure

INIBITORI NEPRILISINA

Outline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan

Patient details GP details Specialist details Name GP Name Dr Specialist Name Dr R. Horton

Biomarker-guided HF: What have we learned (so far)?

Updates in Congestive Heart Failure

LCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Post MI LVSD Teach and Treat

Chronic heart failure in adults: diagnosis and management

Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set

Heart Failure Medications: Who Needs What Drug Now? Disclosures

Heart Failure. GP Update Refresher 18 th January 2018

Frimley Health Area Prescribing Committee

The National Heart Failure Audit 2010/2011

Heart Failure in 2012 with reference to NICE Guidance Dr Maurice Pye Consultant Cardiologist York District Hospital

REVIEW OF HEART FAILURE INDICATORS IN CHESHIRE AND MERSEYSIDE

The Patient Journey through Heart Failure Primary Care Handout

Practical considerations for the use of ARNI in CHF: clinical cases. J. Parissis, Heart Failure Clinic, University of Athens, Athens, Greece

Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure

The Failing Heart in Primary Care

Heart failure in diabetes: consequences for diagnosis and therapy

Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP

CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION

Heart Failure Clinician Guide JANUARY 2016

BNP. Daniel J. Fink, MD, MPH Director, Core Laboratory New York Presbyterian Hospital Columbia University Medical Center New York, New York

Heart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist

Heart Failure with Reduced EF. Dino Recchia, MD, FACC, FHFSA

The new Guidelines: Focus on Chronic Heart Failure

DISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE

CLINICAL PRACTICE GUIDELINE

Chronic heart failure

Treating HF Patients with ARNI s Why, When and How?

Heart Failure Update. Chim Lang

Innovation therapy in Heart Failure

RAAS blocker + B Blocker Troubleshooting

ECG in CRT patients & novel HF therapies. Δημήτριος M. Κωνσταντίνου Ειδικός Καρδιολόγος, MD, MSc, PhD, CCDS Πανεπιστημιακός Υπότροφος

Heart Failure with preserved ejection fraction (HFpEF)

LCZ696: LA NUOVA RIVOLUZIONE NELLA TERAPIA DELLO SCOMPENSO CARDIACO. Dario Leosco Università di Napoli Federico II

Evaluation of a diagnostic pathway in heart failure in primary care, using electrocardiography and brain natriuretic peptide guided echocardiography

Heart Failure: Combination Treatment Strategies

Biomarkers in Heart Disease. Felix J. Rogers, DO, FACOI April 29, 2018

What s new in 2016 Guidelines of the European Society of Cardiology? HEART FAILURE. Marc Ferrini (Lyon Fr)

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.

REVIEW ARTICLE. Sacubitril/valsartan Use for the Hospitalist Mitchell Padkins 1, James Hart 1, Rachel Littrell 2

Title BRITISH SOCIETY FOR HEART FAILURE NATIONAL HEART FAILURE AUDIT APRIL MARCH 2016

Heart Failure: Guideline-Directed Management and Therapy

Heart Failure Management Policy and Procedure Phase 1

Target dose achievement of evidencebased medications in patients with heart failure with reduced ejection fraction attending a heart failure clinic

Heart.org/HFGuidelinesToolkit

National Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008

Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece

2017 Summer MAOFP Update

β 1 Adrenergic Receptor Polymorphism-Dependent Differences

2017 ACC/AHA/HFSA HF guidelines. Advances in the Use of Biomarkers in Heart Failure Patients. Outline

Inverclyde CHP Protected Learning Event- Heart Failure

Title BRITISH SOCIETY FOR HEART FAILURE NATIONAL HEART FAILURE AUDIT

Clinical guideline Published: 25 August 2010 nice.org.uk/guidance/cg108

The clinical value of natriuretic peptide testing in heart failure

Biomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed

Therapeutic Targets and Interventions

eplerenone 25, 50mg film-coated tablets (Inspra ) SMC No. (793/12) Pfizer Ltd

Mihai Gheorghiade MD

Heart Failure with Preserved EF (HFPEF) Epidemiology and management

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Citation. What is New in the 2013 ACC/AHA HF Guideline. Dimensions in Heart and Vascular Care Penn State Heart and Vascular Institute

Μαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό

Heart Failure Update. Bibiana Cujec MD May 2015

Chronic. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Michael G. Shlipak, MD, MPH

State-of-the-Art Management of Chronic Systolic Heart Failure

Transcription:

New NICE Heart Failure Guidelines 2018 - What do they mean for primary and secondary care, and patients? Prof Ahmet Fuat PhD FRCGP FRCP PG Dip (Cardiology) GP & GPSI Cardiology Darlington Professor of Primary Care Cardiology Durham University President Primary Care Cardiovascular Society

Plan Previous guidelines NICE 2018 Quality standards Local HF clinic data Areas of non-compliance Future developments

Chronic heart failure Implementing NICE guidance September 2018 NICE clinical guideline 106

Background The National Institute for Health and Care Excellence (NICE) published an update to the Chronic heart failure in adults: diagnosis and management on 12 th September 2018 1 The NICE guidelines are primarily aimed at primary care and include recommendations for diagnosis, lifestyle, therapeutic and device management. They replace clinical guideline 108 (CG108) which was published in August 2010 2

HF multidisciplinary team Specialist HF team Physician, HFNS, Pharmacist - Diagnose HF (type) - Inform patient - Treat + titrate - Manage HF not responding to treatment Wider team Rehabilitation, palliative care, devices etc

Diagnosis Switch from BNP to NTproBNP for primary care No change in NT probnp thresholds (400 pg/ml) If raised, specialist + echo Speed of referral guided by NT probnp level 2ww for urgent (NTpBNP>2000) vs 6 weeks Remove the urgent referral if previous MI Extended consultation Review within 2w

LEFT VENTRICULAR WALL STRESS TISSUE VENTRICULAR INDUCES NEW BNP SYNTHESIS Pro-BNP 77 N-terminal Pro-BNP 76 BNP 108 108 CIRCULATION H 2 N- 32 a.a. CYS CYS PHE GLY BNP ASP ARG ILE COOH- GLY LEU GLY SER

BNP: Quantitative Marker of HF Volume Pressure ANP Suppression of renin-angiotensin and endothelin CNP BNP = Decreased peripheral vascular resistance (decreased blood pressure) LV Diastolic Dysfunction + LV Systolic Dysfunction + Valvular Dysfunction + RV Dysfunction Increased natriuresis Iwanaga Y. et al. JACC 2006; 47: 742-748

NP cut-offs ESC (2016) - different levels for acute + chronic NICE (2018) - single cut offs for acute and chronic ESC Chronic HF cut-off BNP = 35 pg/ml NTP = 125 pg/ml Acute BNP = 100 pg/ml NTP = 300 pg/ml NICE Chronic HF cut-off NTP = 400 pg/ml

The problem : NT-proBNP and age

Age-dependent values of NT probnp for ruling out heart failure are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care (ICON- PC) Hildebrandt P, Collinson PO, Doughty RN, Fuat A et al Eur Heart J 2010; 31: 1881-9 To investigate age-dependent rule out values in patients in primary care setting with symptoms suggestive of heart failure, to compare these with present standards and to investigate the influence of gender and vasoactive treatment Ten published and unpublished studies of 5508 patients in primary care who had NT-proBNP measurement performed plus echocardiographic estimation of ejection fraction were identified and analysed.

Group (cut off) n Sensitivity Specificity NPV A: Proposed age related % (95% CI) % (95% CI) % < 50 year (50 pg/l) 783 99.2 (95.4-100.0) 57.2 (53.4-61.0) 99.7 50-75 years (75 pg/l) 3668 94.9 (92.9-96.4) 51.0 (49.2-52.8) 96.8 > 75 years (250 pg/l) 1055 87.9 (83.5-91.5) 53.7 (50.2-57.3) 92.4 C: 2008 ESC Guidelines (Age independent (< 400 ng/l)) < 50 year (400 pg/l) 783 71.4 (62.4-79.3) 97.1 (95.6-98.3) 95.0 50-75 years (400 pg/l) 3668 70.4 (66.7-73.9) 90.6 (89.5-91.6) 93.5 > 75 year (400 pg/l) 1055 82.6 (77.6-86.8) 67.1 (63.6-70.4) 91.4

Conclusions NT-proBNP must now be regarded as having hard evidence and sufficient data to be implemented as a an initial test for the presence of significant LV systolic dysfunction in patients with symptoms arousing clinical suspicion of heart failure Further diagnostic tests such as echocardiography could be reserved for patients with elevated levels or continuing strong suspicion of heart failure. Using age-dependent rule out values will optimize the diagnostic accuracy, minimise the risk of a missed diagnosis of heart failure and rationalise echocardiographic follow-up. Cut-off levels of 50 pg/l (age <50 years), 75 pg/l (50-75 years) and 250 pg/l (>75 years) can be recommended as optimised rule out thresholds.

NT probnp Age Dependent Thresholds based on Hildebrandt P, Collinson P, Fuat A et al EHJ 2010;31:1881-1889 Age < 60 years Age 60-74 years Age > 75 years Raised levels >50pg/ml >100pg/ml >250pg/ml High levels >450pg/ml >900pg/ml >1800pg/ml

Treatment No change in medication / devices B-Blocker + ACEi / ARB for all HFrEF MRA for HFrEF if remains symptomatic Sacubitril/Valsartan 4th line Exercise based rehab when stable (flexible + psychological) Do not routinely restrict salt + water

Communication Care plans for all patients Shared with patient (carers), medical + nursing Across primary and secondary care Diagnosis Treatment Medication, device, rehab etc Social and care needs (including carers) What to look for if problem Who to contact (HFNS)

Primary care team Take over care when clinically stable 6 monthly review Communicate Access specialist services as needed

Research priorities Diuretic regime in advanced HF Optimum imaging strategy (CMR + others) AF and BNP threshold CKD and BNP threshold Risk tools for predicting sudden cardiac death

7 Quality Standards (OP) Diagnosis with echo + specialist assessment Seen within 2 weeks if NP level very high If HFrEF ACEi / Beta-blocker Review within 2 weeks if medication changed 6 monthly review of stable patients Offered exercise-based rehabilitation (Developmental) flexible programme (OOH, home based etc)

9 NICE Quality Standards (IP) Single measurement of BNP if HF new HF suspected Echo within 48 hours if BNP raised Specialist HF team (ward + outreach) All patients have early + continued input from HF team If taking B-B, continue unless problem Start / restart B-B before discharge Start ACEi / ARB + MRA before discharge Stable for 48 hours before discharge FU within 2 weeks of discharge

What s new Increased focus on the role of a core specialist team (MDT) working in collaboration with the primary care team 1. 6 monthly follow up in primary care to ensure better outcomes for heart failure patients 1. Measure N-terminal pro-b-type natriuretic peptide (NT pro-bnp) in people with suspected heart failure including this with previous MI 1. Increased information provision to patients with heart failure to allow better understanding of the options and uncertainties of their condition 1. MRAs should be offered to patients symptomatic on ACEi/ARB and BB 1. Primary care clinicians are able to initiate. Patients who have had an MI should have an NT pro-bnp test prior to referral for echocardiogram 1.

Conclusion Not much that s new or controversial!

HF clinic DMH Established 2002 Professor Fuat + Professor Murphy/SHFNs Included BNP / NT probnp Also clinics at BAH / UHND Local primary and secondary Care Referral guidelines Local HF clinic data

BAH/DMH HF clinic 100% 75% 128 221 231 242 200 155 HF N 50% 25% 35 87 104 82 127 106 0% 2013 2014 2015 2016 2017 2018

Final diagnosis 32 25 4212145 358 541 HFPEF Not HF HF Alt Cause Poss HFPEF Mixed HFPEF & Other DNA HF Rig HF Pos Mix No 713

CMR or not? 100% 99 75% 327 50% CMRI N 259 25% 386 0% HFPEF HFREF

Heart Failure Clinic Discharge Template Dear Doctor, This patient has been seen and completed their diagnostic and management work up in the Darlington Integrated Heart Failure Service. Diagnosis mild, moderate or severe LVSD/HFPEF/LVDD/VHD etc NYHA Class at diagnosis: NYHA Class at discharge: Investigations Undertaken: Relevant Bloods (BNP, Renal function) - ECG - Chest X-ray - Echocardiogram - Cardiac MRI - Other - Current Medications: (dose and reason maximum dose not achieved) Diuretic - Beta-blocker - Ace inhibitor (or ARB) - Mineralocorticoid antagonist (MRA) - Other relevant drugs (Please remind patient that if diarrhoea, vomiting or any illness that may cause dehydration the patient should stop diuretic, ACEi, ARB and MRA until drinking and eating again. Restart at usual dose) CRT and or ICD Please see this patient every X months in your CHD/HF clinic If deterioration in HF please refer back to specialist heart failure nurse in the community or the HF clinic urgently Yours sincerely,

Prognosis in Heart Failure P =0.003 (95.0% Confidence Interval 1.130-1.815)

Areas for development Pharmacist input Increase capacity (or reduce referrals) to provide urgent + 6 week routine slots Care plans Develop primary care teams NT probnp titration protocol (?) Expand rehabilitation

Other areas 7 day service for HF Community IV diuretics home or lounge S/C furosemide Inpatient HF review Structured review (wherever delivered)

Any further questions... ahmetfuat nhs.net